Supplemental Figure 16 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
Year: 2026
Type: supplementary-materials
Abstract: Evaluation of CDK4/6 inhibitor cross-resistance in FulvR and AbemaR breast cancer models a. MTT growth assay of FulvR vs parental MCF-7 cells treated with indicated concentrations of Abema or b. CDK4/6 inhibitors ribociclib (1.5 µM), palbociclib (200 nM) or Abema (500 nM). c. MTT growth assay of AbemaR versus parental MCF-7 cells, d. F+A versus parental MCF-7 cells, e. FulvR versus parental ZR75-1 cells, or f. AbemaR versus parental ZR75-1 cells treated with ribociclib (1.5 µM), palbociclib (200 nM) or Abema (500 nM). Bars represent mean+standard deviation of %viability normalized to untreated controls within each cell line. All MTT assays were performed in minimum technical quadruplicate at all concentrations in all cell lines. Cell lines are labeled by biological replicate. Statistical analysis was performed utilizing 2-way ANOVA corrected for multiple comparisons comparing all resistant cell lines to parental controls. *p-val<0.05, **p-val<0.01, ***p-val<0.001, ****p-val<0.0001.
Authors: Sarah K. Herzog, Jessica H. Stevens, Guowei Gu, Sandra L. Grimm, Kloma Cardoza, Autumn G.M. Hawkins, Hangqing Lin, Daniela Ramos, Amanda R. Beyer, David G. Edwards, Derek Dustin, Harry J. Yang, Nicole Liang, Ashfia F. Khan, Tasneem Bawa-Khalfe, Daniel J. McGrail, Shiaw-Yih Lin, Cristian Coarfa, Suzanne A.W. Fuqua
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7147446916